Featured Articles
Recent Articles in Industry Journals Featuring The Zitter Group's Data
"Employers, Health Plans, and New Drug Benefit Designs: A Shifting Landscape" - Mark Zitter discusses highlights from The Zitter Group's Managed Care Benefit Design Index in the January/February 2012 edition of American Health & Drug Benefits.
"The Pace of Change in Oncology Management is Greater than the Sum of Its Parts" - Lee Goldberg, Senior Manager, and Tracey McCarrick, Manager, share highlights from the Summer 2011 edition of The Zitter Group's Managed Care Oncology Index in the December 2011 issue of Value-Based Cancer Care.
Increasing competition in the rheumatoid arthritis payer market drives manufacturers to experiment with new contracting initiatives. Data from The Zitter Group's Managed Care Message Monitor is featured in the November 2011 issue of Formulary - "Creative Contracting Initiatives Key for Pharma as Competition in RA Market Increases"
"How Will Biologics Fit Into Healthcare Reform? " and "Employers Struggle to Cope with the Rising Use of Biologics" - Data from The Zitter Group's Managed Care Benefit Design Index is featured in the Winter 2011 issue of Biotechnology Healthcare.
Payers are keeping an eye on the multiple sclerosis category. Data from The Zitter Group's Managed Care Biologics and Injectables Index is featured in the August 8, 2011 issue of The Pink Sheet - "Gilenya Off and Running, But Keeping Pace Long-Range is Key"
"Appropriate Specialty Drug Utilization to Reduce Waste Still a Top Priority" - Data from The Zitter Group's Managed Care Biologics and Injectables Index is featured in the Summer 2011 issue of Biotechnology Healthcare.
Provenge and Jevtana are found to be covered without a PA by 50% of payers. This and other highlights from The Zitter Group's Prior Authorization Tracking Tool for Prostate Cancer are featured in this article from the June 6, 2011 issue of The Pink Sheet.
Managed Care Marketing
To learn more about our unique approach to advisory meetings, download Mark Zitter’s article “The State of the Art in Advisory Meetings” from Pharmaceutical Executive.
Want help navigating the managed care market? Download our Managed Care Strategy Checklist – a basic tool to help you ask the right questions to better plan your managed care approach.
Want to learn more about the pharma-employer relationship? Click here to read our article "Where the Buck Stops" published in the October 2006 issue of Pharmaceutical Executive.
Managed Market Segmentation
Still think that if you’ve seen one managed care organization, you’ve seen one managed care organization? We’ve developed a proprietary approach to market segmentation that delivers real results. To learn more, download this white paper.
With the advent of Medicare Part D, the majority of pharmaceutical products are now reimbursed under an insurance arrangement. For manufacturers, this necessitates a re-thinking of the importance of the health plan Pharmacy and Therapeutics (P&T) Committee review. Now more than ever before, manufacturers need to consider the P&T review in the marketing plans for both marketed and pre-launch products. This free white paper presents a series of case studies in order to illustrate the various ways P&T committees make formulary coverage decisions. The article also provides advice on how to overcome several common obstacles your product may face when reviewed by the P&T committee.
Learn more about Consumer Directed Health Plans. Click here.
Biotechnology and Managed Care
Managed care organizations continue to grow more sophisticated in their management of biotechnology products. For a detailed analysis of the evolution of managed care’s approach to specialty products, download Tom Baker’s article “5 Stages of Biotechnology Management” from the February 2005 issue of Biotechnology Healthcare.
To review some of our research findings from the biotechnology market, download Tom Baker’s article “Specialty Therapies Lose Special Status” from the September 2004 issue of Pharmaceutical Executive.
The Changing Management of Oncology Medicine
As cancer costs have ballooned over the past several years, payers finally have begun the politically delitcate task of managing oncology treatment. Health plans continue to seek methods to curtail the costs associated with cancer care without diminishing the quality of that care. Indeed, both payers and oncologists anticipate significant increases in the aggressiveness of payer oncology management over the next 2 years.
Want to learn more about key trends in payer management of oncology? Read the article "Oncologists Prefer Oral Drugs, Are Resigned to Payer Management" highlighting findings from The Zitter Group's Winter 2011 Managed Care Oncology Index. This article featured in the May 2011 issue of Specialty Pharmacy News.